Company news
Argenica Therapeutics Ltd news in 2024
Argenica Therapeutics Ltd's news releases, calls and decks from 2024, newest first.
Phase 2 Stroke Clinical Trial Update
December 9, 2024
$2.76m R&D Tax Incentive Cash Rebate Received for FY24
November 20, 2024
Quarterly Activities/Appendix 4C Cash Flow Report - updated
October 31, 2024
FDA Grants ODD & RPDD for Second Drug in Treatment of HIE
October 30, 2024
Positive Results in Key IND Enabling Studies
September 25, 2024
Appendix 4E & Annual Report to 30 June 2024
August 28, 2024
ARG-007 Reduces Effects of TBI in Preclinical Study
May 14, 2024
DSMB Confirms Safety of First Patients Dosed
April 28, 2024
Argenica Successfully Completes $12.0m Placement
April 11, 2024
Patient Dosing Milestone Achieved in Phase 2 Stroke Trial
April 9, 2024
First Patient Dosed in Phase 2 Stroke Trial of ARG-007
March 27, 2024
FDA Grants Rare Pediatric Disease Designation For HIE
March 24, 2024
Phase 2 Manufacturing Completed & Trial Update
February 11, 2024
Decks in 2024
- Shareholder Meeting (November 2024)
Shareholder meeting · 27 slides · Nov 13, 2024
- Investor Presentation (October 2024)
Investor deck · 24 slides · October 2024
- BioShares July 2024
Conference · 17 slides · July 2024